Search Results

Echosens announced the appointment of Victor de Lédinghen, MD PhD, as the company’s new Chief Medical Officer.

Inventiva and Echosens announce their collaboration in raising awareness about NASH and increase access to screening for patients at risk of developing NASH.

Echosens FibroScan ® Improves Quality of Care at America’s Veterans Health Administration Facilities, Provides Early Detection and Monitoring of Liver Disease.

Echosens Presents Robust Research at 2022 AASLD Liver Meeting: Noninvasive FibroScan ® Technology Recognized as Critical Component to Optimize Liver Health Management.

Echosens and Novo Nordisk A/S announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis and increase awareness of the disease among patients, healthcare providers and other stakeholders.

Echosens Presents Symposium & Democenter at EASL International Liver Congress™ 2022: FibroScan ® Solutions Bringing New Guidelines to Life, New FibroScan GO Demonstrations.

Echosens is pleased to announce that the “American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings” states that transient elastography is preferred to quantify liver fat and fibrosis vibration-controlled transient elastography for risk stratification.

As we approach October’s National Liver Health Awareness Month, Echosens, a manufacturer of non-invasive diagnostic technology, FibroScan®, is urgently calling attention to the importance of prioritizing liver health.

Echosens, a high-technology company offering the FibroScan® portfolio of solutions, is pleased to announce that the latest Baveno VII guidelines fully support the effectiveness of FibroScan technologies for the management of patients with advanced chronic liver disease, providing a powerful level of support for its use among specialists.